Protagonist Therapeutics (PTGX) Tops Q4 EPS by 58c

Protagonist Therapeutics (NASDAQ: PTGX) reported Q4 EPS of $0.44, $0.58 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $60 million versus the consensus estimate of $40 million.

For earnings history and earnings-related data on Protagonist Therapeutics (PTGX) click here.

You May Also Be Interested In

• Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
• Zumiez, Inc. (ZUMZ) Misses Q2 EPS by 6c, Misses on Revenue; Offers Q3 Guidance
• Adobe beats Q3 targets, but soft Q4 sales guidance triggers dip